Sam-A Pharm KRX:009300KOSDAQ
삼아제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Sam-A Pharm reported revenue of ₩18.8bn, up 7.8% year on year, and operating profit of ₩1.9bn. Sam-A Pharm (삼아제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Sam-A Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩18.8bn | +7.8% | ₩1.9bn margin 10.0% | ₩4.4bn |
| Q1 2026 | ₩17.6bn | -28.0% | ₩2.1bn margin 11.8% | ₩2.2bn |
| Q4 2025 derived | ₩20.8bn | +5.8% | ₩2.7bn margin 12.8% | ₩4.0bn |
| Q3 2025 | ₩15.1bn | -27.9% | −₩1.1bn margin −7.4% | −₩54m |
| Q2 2025 | ₩17.4bn | -30.4% | ₩2.0bn margin 11.5% | ₩2.7bn |
| Q1 2025 | ₩24.5bn | -18.2% | ₩7.4bn margin 30.4% | ₩6.3bn |
| Q4 2024 derived | ₩19.6bn | -22.8% | ₩3.9bn margin 19.8% | ₩4.3bn |
| Q3 2024 | ₩21.0bn | -5.2% | ₩1.6bn margin 7.4% | ₩2.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Sam-A Pharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Sam-A Pharm news Korean headlines
-
삼아제약 항생제 일부 회수…록시트로마이신 불순물 초과 우려
1 more on this story · 1 outlets
- 삼아제약 항생제 일부 회수…록시트로마이신 불순물 초과 우려알파경제 · Sep 18 08:51